Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis

This phase 2, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of lebrikizumab, an interleukin (IL)-13 monoclonal antibody, alone or with background pirfenidone therapy, in patients with idiopathic pulmonary fibrosis (IPF). Patients with IPF aged ≥40 years with fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Maher, Toby M., Costabel, Ulrich, Glassberg, Marilyn K., Kondoh, Yasuhiro, Ogura, Takashi, Scholand, Mary Beth, Kardatzke, David, Howard, Monet, Olsson, Julie, Neighbors, Margaret, Belloni, Paula, Swigris, Jeffrey J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859504/
https://www.ncbi.nlm.nih.gov/pubmed/33008934
http://dx.doi.org/10.1183/13993003.02442-2019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859504/
https://www.ncbi.nlm.nih.gov/pubmed/33008934
http://dx.doi.org/10.1183/13993003.02442-2019

Ejemplares similares